Will Pricing For Gilead’s Sovaldi Set A Ceiling In HCV, Lead To A Price War?
Gilead’s wholesale acquisition cost of $1,000-a-day for Sovaldi met with immediate backlash, as well as foreboding comments from a leading PBM. Observers anticipate a possible pricing war between Gilead and other companies developing new regimens for HCV.
You may also be interested in...
The view from 2020: Scrip looks back at the most successful commercial launches of the decade.
Brand drug companies might be able to use patent settlements with generic and biosimilar makers to get out of the drug price negotiations that will be created under the US legislation nearing enactment, but sponsors could run into regulatory and antitrust obstacles.
A preliminary analysis of Russian Phase III results for azvudine, China's first home-grown antiviral for COVID-19, shows it reached two primary endpoints, but a separate Chinese study produced mixed results.